Post by Wyss Institute at Harvard University

The extraordinary effectiveness of SARS-CoV-2-specific mRNA vaccines has significantly softened the blow of COVID-19 and inspired the development of mRNA vaccines to also combat other infectious pathogens. However, the immune responses produced by COVID-19 mRNA vaccines vary considerably between people and their duration is limited. A multi-disciplinary research team at the Wyss Institute, Dana-Farber Cancer Institute, and collaborating institutions now advanced their recently developed highly versatile DoriVac DNA origami nanotechnology that is both vaccine and adjuvant as an alternative to current vaccine platforms. As published in Nature Biomedical Engineering, DoriVac vaccines made with different viral antigens produce potent antigen-specific antibody-mediated and T cell-mediated responses in mice as well as in a forward-looking pre-clinical in vitro model of the human lymph node engineered using the Wyss Institute’s microfluidic human Organ Chip technology. Learn more: https://lnkd.in/eMvhaPfw